# Oligonucleotide Therapeutics Market Report: Size, Share & Trends

> The Global Oligonucleotide Therapeutics market stood at USD 6,718.5 Mn in 2025 and will reach USD 20,718.1 Mn by 2035, an 11.92% CAGR. Antisense Oligonucleotides hold 44.0% of revenue and Neurological Disorders are the largest application at 32.0%. North America leads with 39.76% share, while Asia Pacific grows fastest, led by South Korea's 14.1% CAGR, according to Vectomat Insights.

- Publisher: Vectomat Insights
- Report code: VMI-1-1-15389
- Published: 2026-11-13
- Canonical URL: https://www.vectomatinsights.com/report/oligonucleotide-therapeutics-market
- Base year 2025: USD 6,718.5 Mn
- Forecast 2035: USD 20,718.1 Mn
- CAGR 2026–2035: 11.92%

## Key insights

- The Global Oligonucleotide Therapeutics market grows from USD 6,718.5 Mn in 2025 to USD 20,718.1 Mn by 2035, an 11.92% CAGR over 2026–2035.
- Antisense Oligonucleotides are the dominant type at 44.0% of 2025 revenue (USD 2,956.1 Mn), while siRNA, at 36.0%, rises to USD 8,781.3 Mn by 2035 and overtakes antisense.
- Splice-switching oligonucleotides, microRNA mimics and inhibitors are the fastest-growing type, at a 19.13% CAGR from USD 268.7 Mn, helped by conjugated exon skippers such as Dyne's z-rostudirsen.
- Neurological Disorders are the dominant application at 32.0% (USD 2,149.9 Mn), because intrathecal antisense drugs such as Spinraza are dosed for life; Cardiometabolic Disease grows fastest, at 16.19%.
- Hospitals & Specialty Clinics are the dominant end user at 53.4% of revenue, since intrathecal and intravenous drugs need specialist administration; Biopharma Manufacturers grow at 17.35% and become the largest end user by 2035.
- North America leads with 39.76% of 2025 revenue (USD 2,671.5 Mn), with the United States at USD 2,096.2 Mn.
- Asia Pacific is the fastest-growing region, with South Korea growing at a 14.1% CAGR to about USD 1,206.1 Mn by 2035 on the back of oligonucleotide API manufacturing.
- Big pharma is buying delivery technology: Novartis's USD 12.0 billion Avidity acquisition and Sanofi's USD 2.2 billion Dynavax deal both completed in 2026.
- Two 2026 outcome-trial misses, in ATTR cardiomyopathy and Lp(a), mean the cardiometabolic shift will run through triglyceride and LDL indications first.

## Figures

![Oligonucleotide therapeutics market size — USD 6,718.5 Mn (2025) to USD 20,718.1 Mn (2035) | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/oligonucleotide-therapeutics-market/ae535b0c78039a25/oligonucleotide-therapeutics-market-size-vmi.png) — The oligonucleotide therapeutics market grows from USD 6,718.5 Mn in 2025 to USD 20,718.1 Mn by 2035, an 11.92% CAGR. Source: Vectomat Insights, Oligonucleotide Therapeutics Market Report.
![Oligonucleotide therapeutics market drivers, restraints, opportunities and challenges | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/oligonucleotide-therapeutics-market/ae535b0c78039a25/oligonucleotide-therapeutics-market-droc-vmi.png) — New cardiometabolic labels and manufacturing capacity drive the oligonucleotide therapeutics market, while confirmatory-trial risk and costly synthesis restrain it. Source: Vectomat Insights, Oligonucleotide Therapeutics Market Report.
![Oligonucleotide therapeutics market share by region, 2025 — North America 39.76% | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/oligonucleotide-therapeutics-market/ae535b0c78039a25/oligonucleotide-therapeutics-market-regional-share-vmi.png) — North America holds 39.76% of the 2025 oligonucleotide therapeutics market, ahead of Europe at 26.07% and Asia Pacific at 24.1%, the fastest-growing region. Source: Vectomat Insights, Oligonucleotide Therapeutics Market Report.
![Oligonucleotide therapeutics market segmentation overview — type, application, route, end user | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/oligonucleotide-therapeutics-market/ae535b0c78039a25/oligonucleotide-therapeutics-market-segments-vmi.png) — Antisense Oligonucleotides, Neurological Disorders, Subcutaneous and Hospitals & Specialty Clinics lead their segmentation dimensions in 2025. Source: Vectomat Insights, Oligonucleotide Therapeutics Market Report.
![Oligonucleotide therapeutics market share by type, 2025 — Antisense Oligonucleotides 44.0% | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/oligonucleotide-therapeutics-market/ae535b0c78039a25/oligonucleotide-therapeutics-market-type-share-vmi.png) — Antisense Oligonucleotides hold the largest type share of the oligonucleotide therapeutics market in 2025, at 44.0%. Source: Vectomat Insights, Oligonucleotide Therapeutics Market Report.
![Oligonucleotide therapeutics market share by end user, 2025 — Hospitals & Specialty Clinics 53.4% | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/oligonucleotide-therapeutics-market/ae535b0c78039a25/oligonucleotide-therapeutics-market-end-user-share-vmi.png) — Hospitals & Specialty Clinics hold the largest end user share of the oligonucleotide therapeutics market in 2025, at 53.4%. Source: Vectomat Insights, Oligonucleotide Therapeutics Market Report.
![Oligonucleotide therapeutics type mix by region — North America, Europe, Asia Pacific | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/oligonucleotide-therapeutics-market/ae535b0c78039a25/oligonucleotide-therapeutics-market-regional-segments-vmi.png) — Antisense Oligonucleotides lead the type mix in all three largest regions, while North America carries the highest siRNA share at 37.5%. Source: Vectomat Insights, Oligonucleotide Therapeutics Market Report.
![Oligonucleotide therapeutics competitive positioning — commercial scale vs delivery breadth | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/oligonucleotide-therapeutics-market/ae535b0c78039a25/oligonucleotide-therapeutics-market-competitive-landscape-vmi.png) — Alnylam, Ionis, Novartis and Biogen combine the largest approved portfolios with broad delivery platforms, while Dyne and Wave compete on new delivery chemistry. Source: Vectomat Insights, Oligonucleotide Therapeutics Market Report.
![Oligonucleotide therapeutics market at a glance — USD 20,718.1 Mn by 2035, 11.92% CAGR | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/oligonucleotide-therapeutics-market/ae535b0c78039a25/oligonucleotide-therapeutics-market-key-numbers-vmi.png) — The oligonucleotide therapeutics market reaches USD 20,718.1 Mn by 2035 at an 11.92% CAGR, led by North America and growing fastest in Asia Pacific. Source: Vectomat Insights, Oligonucleotide Therapeutics Market Report.
![United States oligonucleotide therapeutics market — USD 2,096.2 Mn (2025) to USD 5,793.1 Mn (2035) | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/oligonucleotide-therapeutics-market/ae535b0c78039a25/oligonucleotide-therapeutics-market-united-states-snapshot-vmi.png) — The United States oligonucleotide therapeutics market grows from USD 2,096.2 Mn in 2025 to USD 5,793.1 Mn by 2035 at a 10.7% CAGR. Source: Vectomat Insights, Oligonucleotide Therapeutics Market Report.
![Germany oligonucleotide therapeutics market — USD 489.1 Mn (2025) to USD 1,303.6 Mn (2035) | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/oligonucleotide-therapeutics-market/ae535b0c78039a25/oligonucleotide-therapeutics-market-germany-snapshot-vmi.png) — Germany's oligonucleotide therapeutics market grows from USD 489.1 Mn in 2025 to USD 1,303.6 Mn by 2035 at a 10.3% CAGR. Source: Vectomat Insights, Oligonucleotide Therapeutics Market Report.
![South Korea oligonucleotide therapeutics market — USD 322.5 Mn (2025) to USD 1,206.1 Mn (2035) | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/oligonucleotide-therapeutics-market/ae535b0c78039a25/oligonucleotide-therapeutics-market-south-korea-snapshot-vmi.png) — South Korea's oligonucleotide therapeutics market grows from USD 322.5 Mn in 2025 to USD 1,206.1 Mn by 2035 at a 14.1% CAGR. Source: Vectomat Insights, Oligonucleotide Therapeutics Market Report.

## Market size (USD million)

| Year | Value |
|---|---|
| 2023 | 5,983.6 |
| 2024 | 6,408.2 |
| 2025 | 6,718.5 |

## Share by Type (2025)

| Segment | Share | USD Mn |
|---|---|---|
| Antisense Oligonucleotides | 44% | 2,956.1 |
| siRNA | 36% | 2,418.7 |
| Aptamers | 10% | 671.9 |
| CpG Oligonucleotides | 6% | 403.1 |
| Splice-switching oligonucleotides, microRNA mimics and inhibitors | 4% | 268.7 |

## Share by Application (2025)

| Segment | Share | USD Mn |
|---|---|---|
| Neurological Disorders | 32% | 2,149.9 |
| Oncology | 28% | 1,881.2 |
| Cardiometabolic Disease | 18% | 1,209.3 |
| Rare Genetic Disease | 14% | 940.6 |
| Ophthalmic, infectious and autoimmune diseases | 8% | 537.5 |

## Share by Route of Administration (2025)

| Segment | Share | USD Mn |
|---|---|---|
| Subcutaneous | 51.9% | 3,485.3 |
| Intravenous | 26% | 1,746.8 |
| Intrathecal | 12% | 806.2 |
| Intravitreal, intramuscular, intranasal and inhaled routes | 10.1% | 680.2 |

## Share by End User (2025)

| Segment | Share | USD Mn |
|---|---|---|
| Hospitals & Specialty Clinics | 53.4% | 3,590.2 |
| Biopharma Manufacturers | 32.4% | 2,176.2 |
| Academic & Research Institutes | 14.2% | 952.1 |

## Regional share

| Region | Share | USD Mn |
|---|---|---|
| North America | 39.76% | 2,671.5 |
| Europe | 26.07% | 1,751.3 |
| Asia Pacific | 24.1% | 1,619.4 |
| Latin America | 5.3% | 356.1 |
| The Middle East | 3.04% | 204.2 |
| Africa | 1.73% | 116.0 |

## Key companies

- Ionis Pharmaceuticals (United States): Antisense oligonucleotides (LICA and gapmer chemistries) in cardiometabolic, neurology and rare disease
- Alnylam Pharmaceuticals (United States): GalNAc-conjugated and CNS-targeted siRNA, led by the Amvuttra TTR franchise
- Sarepta Therapeutics (United States): PMO exon-skipping antisense for Duchenne muscular dystrophy, plus an siRNA pipeline
- Biogen (United States): Intrathecal antisense for spinal muscular atrophy (Spinraza) and SOD1 ALS (Qalsody)
- Novartis (Switzerland): siRNA (Leqvio), antisense (pelacarsen) and antibody-oligonucleotide conjugates
- Sanofi (France): siRNA for hemophilia (Qfitlia) and the CpG 1018-adjuvanted vaccine Heplisav-B
- AstraZeneca (United Kingdom): Antisense for transthyretin amyloidosis (Wainua/Wainzua, partnered with Ionis)
- Astellas Pharma (Japan): Intravitreal aptamer Izervay (avacincaptad pegol) for geographic atrophy
- Nippon Shinyaku (Japan): PMO exon-skipping antisense for Duchenne muscular dystrophy (Viltepso, brogidirsen)
- Arrowhead Pharmaceuticals (United States): TRiM-platform siRNA for cardiometabolic and pulmonary disease
- Wave Life Sciences (Singapore): Stereopure antisense, GalNAc-siRNA and RNA editing
- Dyne Therapeutics (United States): Fab-conjugated oligonucleotides for muscle diseases (FORCE platform)
- City Therapeutics (United States): Next-generation RNAi for tissues beyond the liver
- ST Pharm (South Korea): Contract development and manufacturing of oligonucleotide APIs
- Bachem (Switzerland): Contract manufacturing of peptide and oligonucleotide APIs

## FAQs

### What is the forecast CAGR for the oligonucleotide therapeutics market?

The market grows at an 11.92% CAGR over 2026–2035, from USD 6,718.5 Mn in 2025 to USD 20,718.1 Mn in 2035. Every type grows in absolute value over the forecast period. By type, splice-switching oligonucleotides and microRNA mimics and inhibitors grow fastest at 19.13%, CpG oligonucleotides at 16.44% and siRNA at 13.76%, while antisense grows at 8.40% from the largest base, according to Vectomat Insights.

### Which application segment grows fastest?

Cardiometabolic Disease is the fastest-growing application, at a 16.19% CAGR from USD 1,209.3 Mn in 2025 to USD 5,423.5 Mn in 2035, driven by triglyceride and LDL-cholesterol drugs such as Tryngolza, Redemplo and Leqvio. Oncology, at 28.0%, grows more slowly at 8.15% a year. Neurological Disorders remain the largest application, at 32.0% of 2025 revenue and USD 7,633.7 Mn by 2035, according to Vectomat Insights.

### How are oligonucleotide drugs administered?

Subcutaneous injection is the main route, at 51.9% of 2025 revenue (USD 3,485.3 Mn), because GalNAc-conjugated siRNA and antisense drugs reach the liver from a small monthly to twice-yearly dose. Intrathecal revenue rises from USD 806.2 Mn to USD 4,390.3 Mn by 2035. Intrathecal delivery for CNS diseases is the fastest-growing route at 18.47% a year, and intravenous revenue grows at 14.89% as muscle-targeting conjugates launch, according to Vectomat Insights.

### Why is Asia Pacific the fastest-growing region?

Asia Pacific is adding both manufacturing capacity and patient access. South Korea, worth USD 322.5 Mn in 2025, grows at a 14.1% CAGR as ST Pharm scales oligonucleotide API production, and Japan grows at 12.2%. The region's share rises from 24.1% of global revenue in 2025. China's NMPA approved Sanofi's Qfitlia in December 2025, and Novartis signed a deal worth up to USD 5.2 billion with China's Argo Biopharma, according to Vectomat Insights.

### How is the oligonucleotide manufacturing supply chain changing?

Demand for prevalent-disease drugs is outgrowing solid-phase synthesis, and purification is the main bottleneck. Alnylam is investing USD 250 million in enzymatic-ligation manufacturing, ST Pharm won a KRW 89.7 billion API order in March 2026 and Bachem plans a large-scale plant in Switzerland. New capacity typically takes two to three years to qualify. Biopharma Manufacturers grow at 17.35% a year to USD 10,779.6 Mn by 2035, according to Vectomat Insights.

### What opportunities exist beyond liver-targeted oligonucleotides?

Delivery to muscle, heart and the central nervous system is the main opportunity. Novartis acquired Avidity's antibody-oligonucleotide conjugates for about USD 12.0 billion, Dyne filed z-rostudirsen for Duchenne muscular dystrophy in May 2026, and City Therapeutics raised USD 99.5 million for extrahepatic RNAi. These programs target muscle and CNS diseases with few treatments. Obesity is another frontier, with Wave's WVE-007 in development, according to Vectomat Insights.

### How was the oligonucleotide therapeutics market sized?

The model is built bottom-up from product-level net sales and royalty disclosures, mapped to type, application, route and end user, then reconciled top-down against the reported revenue of the profiled companies. Country values are checked against regional totals. Primary interviews with developers, CDMOs, prescribers and market-access specialists test volumes and pricing, and segments and regions are reconciled to the 2025 total, according to Vectomat Insights.

Cite as: Vectomat Insights (2026). Oligonucleotide Therapeutics Market Report. https://www.vectomatinsights.com/report/oligonucleotide-therapeutics-market